Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (1367)	1/16/2000 2:26:00 PM
From: Sean Janzen	Read Replies (1) \| Respond to of 1501

IZP has outstanding management and the future looks very bright. Here's an interesting article on the biotech industry. Surge expected to continue for biotechnology industry azcentral.com I'd still like to see IZP do an IPO onto NASDAQ. The climate looks good. My only concern is IZP might be too early in its development. If any of our reader are in New York in February you might want to attend this, IZP's next, conference. Its free to qualified investors. A couple of the investor sessions of interest to IZP investors: New Developments in Respiratory Disease Inflammation and A New Pathway to Stop Disease in its Tracks. February 15-16, 2000 Bio CEO & Investor Conference, New York The Program The program is built around a series of 12-Investor Sessions and 6-CEO Roundtables. The program also includes a Plenary Session, Individual Company Presentations, networking receptions and industry luncheons. The First Annual CEO & Investor Conference held in February 1999 was oversubscribed. Instead of attracting 350 participants, more than 750 people attended the conference. The second conference, which is expected to be bigger and better, will take place in a new location, the Waldorf-Astoria Hotel, in New York City. 12-Investor Sessions The Investor Sessions are focused on a therapeutic area or technology category. The panels are moderated by an industry analyst from one of the sponsoring investment banks and an industry expert and include up to six biotech CEOs. The CEOs represent companies with complementary and/or competitive approaches to the topic. The discussion and Q&A that follows allows the investors to get a horizontal view of the sector and its overall market opportunities. Investors who attended the first conference were unanimous in their support of this format. - Genomics: Where's the Beef? - Beyond Chemotherapy: Monoclonal Antibodies & Cancer - Tools for Greater R&D Productivity - New Developments in Respiratory Disease - From the Thrill of Victory to the Agony of Defeat: HIV & the Development of Drugs for Chronic Viral Infections - Inflammation: A New Pathway to Stop Disease in its Tracks - Anti-Angiogenesis: Exciting Approach for the Next Millennium - Emerging Concepts in Immunotherapy - Combination Therapies: Is it in Our Future? - Approaches to Cacer Treatment in the New Millennium - Central Nervous System Disorders 6-CEO Roundtables The CEO Roundtables are focused on issues that are important to the growth of the industry and the health of individual companies. The panels, which are organized and moderated by industry supporters, typically include a number of CEOs who can relate their experience with the topic being discussed. The roundtables are intended to be fully interactive. - Accessing Foreign Capital: Why Should a Biotech CEO Bother? - New Business Models to Succeed in the Biotechnology Industry - High-Performing Strategic Alliances - Biotech-to-Biotech Mergers: Case Studies - Maximizing the Value and Potential of IP Assets in the New Millennium and Beyond Who Should Attend All biotech CEOs, new and current biotechnology investors, Senior Pharmaceutical Research or Licensing executives, CRO executives, and the media. Keynote Speakers Moses Judah Folkman, Director of Surgical Research Laboratory at Children's Hospital, Boston Jurgen Drews, former President, Global Research and Member of the Executive Committee of the Roche Group, Hoffmann-LaRoche Inc.

To: David Culver who wrote (1367)	1/16/2000 2:29:00 PM
From: Chuca Marsh	Respond to of 1501

OT-( partial PR, forgive me, yet it is Biotech On Topic-BOT!)( I never used to say that in the Old Days HERE!)I agree guys, this is the year of TECH and NEWTECH and BIOTECH, the people that understand that will profit. Thanks for the hold pattern of all the past trails and whatevers. I invite you to the IMMC thread if you want to talk, Type II Diabetes Pills with a twist. Not a sour lemon, SEC Disclsoure on thread there, a sweet place in the stomach: EPTC ...dual play at IMMC SI thread also NOW: techstocks.com siliconinvestor.com above for NON MEMBERS Below : techstocks.com above ONE for SI Members ...we are up to 10 posts at IMMC and Nearing 100 at RBs old EPTC Board: ragingbull.com Misc (Biotech) : IMMC-IMMUNIS CORP. Chucka